Skip to main content
Search
Main content
Alzheimer's & dementia : the journal of the Alzheimer's Association
Published

Biomarker-informed differences in treatment-associated cognitive decline in dementia with Lewy bodies

Authors

Cen Chen, Hong Xu, Anna Rennie, Tobias Borgh Skillbäck, Silke Kern, Henrik Zetterberg, Linus Jönsson, Daniel Ferreira, Maria Eriksdotter

Abstract

Alzheimers Dement. 2026 Nov;22(11):e72021. doi: 10.1002/alz.72021.

ABSTRACT

INTRODUCTION: Alzheimer's disease (AD) co-pathology is common in dementia with Lewy bodies (DLB) and has been linked to worse clinical outcomes. Whether AD biomarker status influences cognitive trajectories and treatment-associated cognitive trajectories in DLB remains unclear.

METHODS: We conducted a retrospective cohort study by linking the Swedish Registry for Cognitive/Dementia Disorders (SveDem) with cerebrospinal fluid (CSF) biomarker data. Participants were individuals with incident DLB diagnosed between 2010 and 2020 who had CSF amyloid-β42/amyloid-β40 (Aβ42/40) or Aβ42/phosphorylated tau (p-tau) measurements and longitudinal Mini-Mental State Examination (MMSE) assessments during follow-up. Linear mixed-effects models incorporating inverse probability of treatment and censoring weighting estimated cognitive trajectories according to AD biomarker status and antidementia treatment.

RESULTS: Among 360 participants (mean age 73.3 years; 33.9% women), 196 (54.4%) were AD biomarker-positive. AD biomarker-positive participants exhibited faster cognitive decline than biomarker-negative participants, with an additional decline of 0.80 MMSE points per year (95% confidence interval [CI], -1.17 to -0.43). Overall, cholinesterase inhibitor (ChEI) use was associated with slower cognitive decline than no treatment, whereas associations for memantine were less consistent. In biomarker-stratified analyses, ChEI use was associated with slower decline among AD biomarker-positive participants but not among biomarker-negative participants. Formal interaction analyses indicated that treatment-associated differences in MMSE change varied according to AD biomarker status.

DISCUSSION: AD biomarker positivity identifies a subgroup of individuals with DLB at higher risk of accelerated cognitive decline. Treatment-associated cognitive trajectories also differed according to AD biomarker status; however, these observational treatment findings require cautious interpretation and confirmation in prospective biomarker-stratified studies.

PMID:43059509 | DOI:10.1002/alz.72021

UK DRI Authors

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg